Open Access

Expression of bcl-2 and p53 in bovine cutaneous fibropapillomas

Infectious Agents and Cancer201510:2

https://doi.org/10.1186/1750-9378-10-2

Received: 25 September 2014

Accepted: 15 December 2014

Published: 12 January 2015

Abstract

Background

Bovine cutaneous fibropapillomas are benign hyperproliferative lesions induced by Bovine Papillomaviruses (BPVs). Bcl-2 is an important anti-apoptotic protein which is expressed in several cancer types. In contrary, p53 is a tumour suppressor protein that mediates cell cycle arrest, apoptosis and senescence in response to cellular stresses.

Findings

Here, we investigated immunohistochemically and biochemically, the expression of bcl-2 and p53 in a subset of BPV positive fibropapillomas and bovine normal skin. Normal skin samples showed a weak signal for both proteins in the cytoplasm of the basal cells. Nine out of twelve (75%) tumour samples stained positive for bcl-2 throughout basal and parabasal layers, with most of cells showing strong cytoplasmic immunoreactivity. Nine out of twelve (75%) fibropapillomas were found to be positive for p53 expression, showing a strong cytoplasmic and perinuclear staining of p53 protein mainly in the basal and parabasal layers.

Conclusions

Our data reveal an altered bcl-2 and p53 immunoreactivity in bovine cutaneous fibropapillomas, suggesting involvement of these two proteins in the cutaneous neoplastic transformation through an impaired apoptotic process.

Keywords

Bovine papillomavirus Cattle Fibropapilloma

Background

Bovine cutaneous fibropapillomas are benign hyperproliferative lesions induced by different BPVs types, infecting both the epithelial cells and the underlying dermis [1]. These lesions usually undergo spontaneous regression, although in some cases the bovines might develop extensive papillomas resulting in debilitated animals that may succumb [1].

BPV infection is supposed to be the most important causal factor in fibropapilloma development and our previous studies on these tumours have demonstrated alterations of GAP junction proteins and signaling transduction pathways [2]. However, the mechanisms underlying cutaneous fibropapilloma development are not yet fully understood.

Papillomaviruses (PVs) are oncogenic viruses causing both benign and malignant tumours in humans as well as in several animal species. These viruses have developed numerous strategies in order to block host-mediated apoptosis, contributing to cancer development [3].

Programmed cell death, known as apoptosis, is a pivotal mechanism of cell death that plays an important role during diverse biological processes, including development, cell differentiation and proliferation [4]. The regulation of cells undergoing apoptosis is controlled by the bcl-2 proteins family; it includes both pro- (i.e. Bax, Bak) and anti-apoptotic proteins (i.e. bcl-2 itself) triggering or blocking, respectively, the release from mythocondria of proteins activating the apoptotic molecular cascade [4]. Generally, cells at proliferative stages express bcl-2, whilst it is downregulated in cells undergoing differentiation; indeed, bcl-2 is expressed in the germinal layer of epithelium, indicating a role in protecting the cells from apoptosis and providing a perpetual supply of cells for differentiation [5]. Several mechanisms have been found to cause bcl-2 dysregulation and cancer, including activating chromosomal translocation [6] and up-regulation upon viral infection: for instance, up-regulated bcl-2 expression has been described in different tumours, including premalignant and malignant lesions of the uterine cervix induced by Human Papillomaviruses (HPVs) [79]. In veterinary oncology, impaired bcl-2 expression has been recorded also in different feline epithelial tumours, such as basal cell tumour, carcinoma in situ and mammary carcinoma [10].

P53 is a tumour suppressor protein that mediates cell cycle arrest, DNA integrity and repairing, apoptosis and senescence in response to specific cellular stresses (e.g. various types of DNA damage, hypoxia, oncogene deregulation, oxidative damage) [11]. As a consequence of stress, p53 translocates from the nucleus to the cell cytoplasm where it directly interacts with and regulates members of the bcl-2 proteins family, including bcl-2 itself. This results in the release of various pro-apoptotic proteins, which in turn activate apoptosis [11].

P53 has a significant role in cell cycle control, therefore the loss of its suppressive function has been reported for different types of human neoplasia and animal tumours, such as BPV induced tumours [1214]. However, studies concerning the expression and the impact of anti-apoptotic protein bcl-2 and the tumour suppressor p53 in BPV induced cutaneous tumours are lacking.

Findings

In this study, we investigated the expression of p53 and bcl-2 in bovine fibropapillomas according to the detailed “Materials and Methods” in the Additional file 1. Histopathologically, the tumours were all classified as cutaneous fibropapillomas. The PCR assay confirmed the presence of the BPV −1/-2 DNA in the tested samples, as detailed in Table 1. The expression of bcl-2 and p53 was assessed by immunohistochemistry and Western blot. Nine out of twelve (75%) fibropapillomas samples stained positive for bcl-2 throughout basal and parabasal layers, with most of cells showing strong cytoplasmic and membrane immunoreactivity (Figure 1A). The normal skin samples showed weak bcl-2 cytoplasmic staining, which was confined to the cells of basal layer (Figure 1B). The intensity and the expression pattern of each sample are summarized in Table 1. A human non- Hodgkin lymphoma used as positive control exhibited a strong cytoplasmic immunoreactivity (Figure 1C). Further, to check whether the expression of bcl-2 influences the rate of cell survival, we determined the apoptotic index (AI) comparing bcl-2 positive versus bcl-2 negative samples, as described in “Materials and Methods” section in Additional file 1. An AI of 43% (±5.2) was observed in bcl-2 negative fibropapillomas, whereas bcl-2 positive samples showed an AI of 37% (±2.57) (data not shown).

Nine out of the 12 (75%) bovine fibropapillomas were found to be positive for p53 expression. In most samples, a strong expression of p53 protein was detected in the basal layer and parabasal layer, where cells with a cytoplasmic and perinuclear staining were recorded (Figure 2A). In the spinous and granular layers, few cells with an intense perinuclear staining were observed. In normal skin samples, the expression of p53 was weak and limited to the cytoplasm of the cells of basal layer (Figure 2B). The positive control represented by human mammary cancer showed a cytoplasmic staining (Figure 2C). To check the specificity of the antibodies used throughout the study, Western blot analysis was performed, showing a band of the expected size for bcl-2 (25KDa) and p53 (53KDa) in the tested samples as well as in HEK293 cell line used as positive control (Figure 3A, 3B).
Table 1

BPV 1/2 DNA presence and bcl-2 and p53 protein expression in normal skin and bovine cutaneous fibropapillomas

Sample

BPV 1/2 DNA

Bcl-2

p53

Staining

Pattern

Intensity

Staining

Pattern

Intensity

T1

+

Yes

Cytoplasmic,

Membranous

+++

Yes

Cytoplasmic

Perinuclear

++

T2

+

Yes

Cytoplasmic,

Membranous

+++

Yes

Cytoplasmic

Perinuclear

+++

T3

+

Yes

Cytoplasmic,

Membranous

++

Yes

Cytoplasmic

Perinuclear

++

T4

+

Yes

Cytoplasmic,

Membranous

++

Yes

Cytoplasmic

Perinuclear

+++

T5

+

Yes

Cytoplasmic,

Membranous

+++

Yes

Cytoplasmic

Perinuclear

+

T6

+

No

No

-

Yes

Cytoplasmic

Perinuclear

+

T7

+

Yes

Cytoplasmic

+++

Yes

Cytoplasmic

+

T8

+

Yes

Cytoplasmic,

Membranous

++

No

No

No

-

T9

+

No

No

-

No

No

No

-

T10

+

Yes

Cytoplasmic,

Membranous

+

Yes

Cytoplasmic

Perinuclear

++

T11

+

No

No

-

No

No

-

T12

+

Yes

Cytoplasmic

++

Yes

Cytoplasmic

Perinuclear

+++

N1

+

Yes

Cytoplasmic

+

Yes

Cytoplasmic

+

N2

+

Yes

Cytoplasmic

+

Yes

Cytoplasmic Perinuclear

++

The presence of BPV 1/2 DNA is indicated by “+”. The cellular pattern of the immunoreactivity is either indicated with cytoplasmic and/or membranous and/or perinuclear. The intensity of immunolabelling for each specimen was scored in a “blind study” on a four-tiered scale: −, absent; +, weak signal or very weak signal; ++, moderate signal; +++, strong signal. “T” stands for tumour samples and “N” stands for normal skin samples.

Figure 1

Bcl-2 expression in bovine cutaneous fibropapillomas and normal skin; (A) bcl-2 is strongly expressed in the cytoplasm and membrane of the neoplastic cells of the basal and parabasal layers (white arrowhead); (B) Normal skin sample showing a weak expression of bcl-2 limited to the cytoplasm of the cells of basal layer (black arrowhead); (C) A positive control represented by human non- Hodgkin lymphoma showed a cytoplasmic immunoreactivity. IHC X 200.

Figure 2

P53 expression in bovine cutaneous fibropapillomas and normal skin; (A) p53 is expressed in the cytoplasm of basal (white arrowhead) and parabasal epithelial cells; note a perinuclear pattern in some cells of the parabasal layer (black arrowhead); (B) Normal skin samples showing a weak p53 cytoplasmic staining, confined to the basal cell layer (white arrow); (C) Epithelial cells of human mammary cancer showed cytoplasmic immunoreactivity (black arrow). IHC, A X 400, B, C X 200.

Figure 3

Western blotting for bcl-2 and p53 proteins in bovine cutaneous fibropapillomas and normal skin.(A) Western blot analysis of bcl-2 in bovine normal skin and fibropapillomas (upper blot); the blot was stripped and reprobed with anti-β-actin antibody to confirm equal loading of proteins in each lane (lower blot). (B) Western blot analysis of p53 in bovine normal skin and fibropapillomas (upper blot); the blot was stripped and reprobed with anti-β-actin antibody to confirm equal loading of proteins in each lane (lower blot).

By immunohistochemistry, two fibropapilloma samples (T9 and T11) did not expressed neither bcl-2 nor p53 proteins. The lack of reactivity might be due to the loss of antigenicity.

Bovine cutaneous fibropapillomas are benign lesions known to affect cattle worldwide. BPV are considered as causative agents of these tumours, inducing the proliferation of both epithelial and dermal cells [1]. Apoptosis is a tightly regulated process that plays an important role in development and homeostasis, responsible for the balance between cell proliferation and cell death, where bcl-2 has been proven to have a central role [6].The deregulation of the normal apoptotic process is considered as an “hallmark” of cancer [5, 7, 15, 16]. In our study we showed that in normal skin bcl-2 protein expression is confined to the cytoplasm of the basal cell layer, which is in agreement to that described in feline, canine and human skin [10, 17]. The basal keratinocyte-restricted expression of bcl-2 suggests that it may protect the cells from apoptosis, being responsible for the proliferation and regeneration of the epithelium [5]. Bcl-2 expression in the cytoplasm and plasma membrane specifically inhibits the cell death, resulting in cell surviving [18]. In BPV positive fibropapillomas, a strong immunoreactivity of bcl-2 was observed in all layers. This is the first time, to the best of our knowledge that bcl-2 is reported to be expressed in the membrane and the cytoplasm of bovine neoplastic cells, suggesting an active pathogenic contribution in protecting these cells by inhibiting the normal apoptotic processes. Similarly, a relatively high bcl-2 expression was recorded in HPV associated epidermodysplasia verruciformis, where the interaction between oncogenic HPV and bcl-2 may result in increased susceptibility toward acquirement of somatic mutations and malignant transformation [16]. We speculate that bcl-2 deregulation maybe a common mechanism in PVs induced cancerogenesis.

In our study, bcl-2 positive samples showed a reduced number of TUNEL positive cells when compared to the bcl-2 negative fibropapillomas. This is in accordance with human counterpart, where in head and neck squamous cell carcinomas the number of apoptotic cells was noted to be reduced in bcl-2 positive tumours when compared to bcl-2 negative tumours [7]. This finding suggests that apoptosis might be regulated by bcl-2 expression also in BPV induced fibropapillomas. Bcl-2 upregulation is one of the potential mechanisms by which tumour cells escape from p53 mediated apoptosis; functional p53 inhibits bcl-2 expression and its anti-apoptotic function, thus altered localization and/or expression of p53 may lead to bcl-2 overexpression and exertion of its anti-apoptotic activity [8].

Normally, a very low expression of p53 protein is detected in cells; in response to cellular stresses, however, the protein is stabilized and cell division is inhibited in order to respond to such damage [19].

Our results indicate that p53 is weakly expressed in basal epithelial cells of normal skin samples. Accordingly, a similar p53 expression pattern in the basal epithelial cells has been recorded in human normal skin, suggesting that it may exert its physiological function in bovine healthy epithelium [15, 20, 21].

Fibropapilloma samples showed a strong cytoplasmic and perinuclear p53 expression in the basal and parabasal cell layers. Cytoplasmic accumulation of p53 has been proposed as a considerable mechanism to disrupt its function as a tumour suppressor and its expression has been reported in different human and animal tumours [22, 23]. Recent findings report cytoplasmic overexpression of p53 in BPV induced equine sarcoids; moreover, a perinuclear p53 expression has been reported in the same tumours, suggesting that p53 alteration contributes to disruption of the equilibrium of cell growth and cell death in BPV associated tumours in different species [12, 13, 24].

However, the higher expression of p53 in epithelial component of fibropapilloma may be due to different stresses followed by a temporary increase of the normal p53 protein or accumulation of mutated p53, resulting in a permanent abnormal form of p53 that is not functional and/or resistant to degradation [25].

Our results indicate that bcl-2 expression may promote the survival of the neoplastic cells possibly depending on p53 impaired expression.

Despite a number of studies have higlighted a role for BPV’s oncogenes in impairing some cellular pathways and leading to neoplastic transformation, nothing is known about a possible interplay among the viral oncoproteins and bcl-2 and p53 dysregulation. Thus, the unraveling of new pathways possibly involved in the pathogenesis of bovine cutaneous fibropapillomas is of a great importance to complete the molecular scenario triggering to the development of these tumours.

In summary, the current study provides evidence for p53 and bcl-2 expression in a majority of BPV-induced bovine tumours, suggesting an involvement of these two proteins in bovine cutaneous fibropapilloma development. Further studies are needed to better understand bcl-2 and p53 function in vivo carcinogenesis.

Declarations

Acknowledgements

The authors wish to express their gratitude to dr. Carlo della Ragione (AORN - A. Cardarelli – Napoli), Dr. Valeria Marina Monetti (Department of Pharmacy – University of Naples Federico II), Prof. Carmen Solcan and Dr. Ionut Bors for their technical support. Part of this work was supported from the Project “PROIECTE DE CERCETARE – sesiunea 2013, University of Applied Science and Environment, Iasi”.

Authors’ Affiliations

(1)
Department of Public Health, Faculty of Veterinary Medicine, University of Agriculture Sciences and Veterinary Medicine
(2)
Department of Veterinary Medicine and Animal Productions, University of Naples Federico II

References

  1. Nasir L, Campo MS: Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids.Vet Dermatol 2008,19(5):243–54. 10.1111/j.1365-3164.2008.00683.xView ArticlePubMedGoogle Scholar
  2. Bocaneti F, Altamura G, Corteggio A, Velescu E, Roperto F, Borzacchiello G: Bovine Papillomavirus: new insights into an old disease.Transbound Emerg Dis 2014. doi:10.1111/tbed.12222Google Scholar
  3. Fuentes-González AM, Contreras-Paredes A, Manzo-Merino J, Lizano M: The modulation of apoptosis by oncogenic viruses.Virol J 2013, 10:182. [Epub ahead of print] 10.1186/1743-422X-10-182View ArticlePubMedPubMed CentralGoogle Scholar
  4. Ulukaya E, Acilan C, Yilmaz Y: Apoptosis: why and how does it occur in biology?Cell Biochem Funct 2011,29(6):468–80. 10.1002/cbf.1774View ArticlePubMedGoogle Scholar
  5. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.Cell 2011, 144:646–74. 10.1016/j.cell.2011.02.013View ArticlePubMedGoogle Scholar
  6. Lawen A: Apoptosis-an introduction.BioEssays 2003, 25:888–96. 10.1002/bies.10329View ArticlePubMedGoogle Scholar
  7. Drenning SD, Marcovitch AJ, Johnson DE, Melhem MF, Tweardy DJ, Grandis JR: Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium.Clin Cancer Res 1998, 4:2913–21.PubMedGoogle Scholar
  8. Grace VM, Shalini JV, Iekha TT, Devaraj SN, Devaraj H: Co-overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix.Gynecol Oncol 2003,91(1):51–8. 10.1016/S0090-8258(03)00439-6View ArticlePubMedGoogle Scholar
  9. Singh M, Srivastava S, Singh U, Mathur N, Shukla Y: Co-expression of p53 and Bcl-2 proteins in human papillomavirus-induced premalignant lesions of the uterine cervix: correlation with progression to malignancy.Tumor Biol 2009, 30:276–85. 10.1159/000259911View ArticleGoogle Scholar
  10. Madewell BR, Candour-Edwards R, Edwards BF, Walls JE, Griffey SM: Topographic distribution of bcl-2 protein in feline tissues in health and neoplasia.Vet Pathol 1999, 36:565–73. 10.1354/vp.36-6-565View ArticlePubMedGoogle Scholar
  11. Vaseva AV, Moll UM: The mitochondrial p53 pathway.Biochim Biophys Acta 2009,1787(5):414–20. 10.1016/j.bbabio.2008.10.005View ArticlePubMedGoogle Scholar
  12. Finlay M, Yuan Z, Morgan IM, Campo MS, Nasir L: Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53.Vet Res 2012, 43:81. 10.1186/1297-9716-43-81View ArticlePubMedPubMed CentralGoogle Scholar
  13. Nixon C, Chambers G, Ellsmore V, Campo MS, Burr P, Argyle DJ, et al.: Expression of cell cycle associated proteins cyclin A, CDK-2, p27 kip1 and p53 in equine sarcoids.Cancer Lett 2005, 221:237–45. 10.1016/j.canlet.2004.08.039View ArticlePubMedGoogle Scholar
  14. Teifke J, Lohr C: Immunohistochemical detection of p53 over expression in paraffin wax-embedded squamous cell carcinomas of cattle, horses, cats and dogs.J Comp Pathol 1996, 114:205–10. 10.1016/S0021-9975(96)80010-7View ArticlePubMedGoogle Scholar
  15. Gunduz K, Demireli P, Vatansever S, Inanir I: Examination of bcl-2 and p53 expressions and apoptotic index by TUNEL method in psoriasis.J Cutan Pathol 2006, 33:788–92. 10.1111/j.1600-0560.2006.00564.xView ArticlePubMedGoogle Scholar
  16. Hussein MR, Al-Badaiwy ZH, Guirgius MN: Analysis of p53 and bcl-2 protein expression in the non-tumorigenic, pretumorigenic, and tumorigenic keratinocytic hyperproliferative lesions.J Cutan Pathol 2004, 31:643–51. 10.1111/j.0303-6987.2004.00244.xView ArticlePubMedGoogle Scholar
  17. Vascellari M, Giantin M, Capello K, Carminato A, Morello EM, Vercelli A, et al.: Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.Vet Pathol 2013, 50:110–21. 10.1177/0300985812447829View ArticlePubMedGoogle Scholar
  18. Hockenbery DM, Nunez G, Milliman C, Screiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.Lett Nat 1990, 348:334–6. 10.1038/348334a0View ArticleGoogle Scholar
  19. Benjamin CL, Stephen E, Ullrich SE, Kripke ML, Ananthaswamy: HN p53 tumor suppressor gene: a critical molecular target for UV induction and prevention of skin cancer.Photochem Photobiol 2008, 84:55–62.PubMedGoogle Scholar
  20. Baran W, Szepietowski JC, Szybejko-Machaj G: Expression of p53 protein in psoriasis.Acta Dermatovenrol APA 2005,14(3):79–83.Google Scholar
  21. Helander SD, Peters MS, Pittelkow MR: Expression of p53 protein in benign and malignant epidermal pathologic conditions.J Am Acad Dermatol 1993, 29:741–8. 10.1016/0190-9622(93)70240-TView ArticlePubMedGoogle Scholar
  22. Hershey AE, Dubielzig RR, Padilla ML, Helfand SC: Aberrant p53 expression in feline vaccine-associated sarcomas and correlation with prognosis.Vet Pathol 2005, 42:805–11. 10.1354/vp.42-6-805View ArticlePubMedGoogle Scholar
  23. Moll UM, LaQuaglia M, Benard J, Riou G: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.Proc Natl Acad Sci U S A 1995, 92:4407–11. 10.1073/pnas.92.10.4407View ArticlePubMedPubMed CentralGoogle Scholar
  24. Bogaert L, Van Poucke M, De Baere C, Dewulf J, Peelman L, Ducatelle R, et al.: Bovine papillomavirus load and mRNA expression, cell proliferation and p53 expression in four clinical types of equine sarcoid.J Gen Virol 2007, 88:2155–61. 10.1099/vir.0.82876-0View ArticlePubMedGoogle Scholar
  25. Seleit IA, Asaad N, Maree A, Wahed MA: Immunohistochemical expression of p53 and Ki-67 in cutaneous lupus erythematosus.J E W D S 2010, 7:5–15.Google Scholar

Copyright

© Bocaneti et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement